PipelineDeveloping Needed and Actionable DiagnosticsVeracyte is advancing the development of diagnostics for thyroid nodules and lung cancer, along with other difficult-to-diagnose lung diseases — all of which have high rates of ambiguous diagnostic test results. We aim to develop products that enable doctors to make better and more efficient treatment decisions that improve patient care and provide cost savings to the healthcare system.Thyroid ProgramIn late 2010, Veracyte successfully launched the Gene Expression Classifier as part of its Afirma Thyroid FNA Analysis for thyroid nodule assessment. Veracyte is embarking on additional genomic tests that will be incorporated into our comprehensive Afirma Thyroid FNA Analysis.Lung ProgramThe lung program is in early biomarker discovery. Similar to our thyroid program, we are employing a whole-genome approach, stringent clinical validation trials that represent the general population, and rigorous analysis. |
